ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0128

Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research

Jheel Bhatt1, Elizabeth Sloan2, Selcan Demir3, Mojca Avramovic4, Seza Özen5, Doruk Erkan6 and Tadej Avcin7, 1Advent Health Orlando, Orlando, FL, 2UT Southwestern, Children's Medical Center, and Scottish Rite for Children, Dallas, TX, 3Eskisehir Osmangazi University, Eskişehir, Turkey, 4University Children's Hospital, Ljubljana, Slovenia, 5Hacettepe University Medical Faculty, Ankara, Turkey, 6Hospital for Special Surgery, New York, NY, 7University Children's Hospital University Medical Center Ljubljana, Ljubljana, Slovenia

Meeting: ACR Convergence 2025

Keywords: antiphospholipid syndrome, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0115–0144) Antiphospholipid Syndrome Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a rare, thrombo-inflammatory autoimmune disease characterized by thrombosis and nonthrombotic manifestations in patients with persistent positive antiphospholipid antibodies, with clinical features that differ from adult APS. Current APS classification criteria are derived from adult data, and pediatric APS data collection is fragmented and inconsistent between institutions and regions. This project aims to develop an international consensus that defines critical data fields to facilitate international registry-based pediatric APS research.

Methods: Data fields were compared from existing International Ped-APS Registry and CARRA Registry, which identifies patients with APS within the lupus cohort. The 2023 ACR/EULAR APS classification criteria were reviewed and systematic literature review of pediatric APS between 2003-2024 was conducted to identify potential data elements for future registries (Figure 1). Delphi surveys were completed by physicians with APS experience, which included pediatric rheumatologists, med/peds rheumatologists, adult rheumatologists, and pediatric hematologists representing 12 countries and two caregiver representatives. Items were scored from 1 (not important) to 9 (very critical). Consensus “in” was reached for core items scored > 7 by > 70% of experts, as well as all items included in the adult 2023 APS Classification Criteria. Consensus “out” was reached for items with average score < 5. The remaining items were labeled “equivocal” for voting at a hybrid consensus meeting. During the meeting, items with >80% agreement were included in the final dataset (either Core or Expanded), and items failing to meet consensus were either excluded or revised and re-evaluated when appropriate. Items scoring >6 were eligible for either Core or Expanded datasets. Items scoring > 5 but < 6 were only voted upon for the Expanded dataset.

Results: Thirty-two Delphi surveys were completed in round 1 and twenty-six in round 2. Two caregiver representatives completed a modified Delphi. Of 316 final candidate items (Figure 2), 72 items reached consensus “in”, 87 items were consensus “out” and 157 “equivocal” items were discussed at the hybrid consensus meeting (Table 1). Nineteen participants voted upon Core and Expanded Datasets for each “equivocal” item. The final dataset included 60 core data elements and 22 expanded data elements, spanning 18 thematic domains.

Conclusion: Through systematic evaluation of existing registries, literature review, and Delphi process, we have identified several critical variables to inform future pediatric APS registries. By leveraging international expertise and integrating it with patient patient perspectives, we are laying a solid foundation for the development of a harmonized dataset to advance pediatric APS research efforts globally.

Supporting image 1Figure 1. Flow diagram of literature review to identify candidate items

Supporting image 2Figure 2. Flow diagram showing selection process of candidate items for Delphi survey to identify critical data fields in pediatric APS registries

Supporting image 3Table 1: List of consolidated core and expanded clinical datasets


Disclosures: J. Bhatt: None; E. Sloan: None; S. Demir: None; M. Avramovic: None; S. Özen: Novartis, 6, Pfizer, 6, Sobi, 6; D. Erkan: Chugai, 5, GlaxoSmithKlein(GSK), 1, 5, 6, Merida Biosciences, 2, NIH, 5, Roche, 1, Roivant Sciences, 2, Star Therapeutics, 1, Up-To-Date, 9; T. Avcin: None.

To cite this abstract in AMA style:

Bhatt J, Sloan E, Demir S, Avramovic M, Özen S, Erkan D, Avcin T. Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/defining-a-consensus-for-critical-data-fields-for-international-pediatric-antiphospholipid-syndrome-research/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/defining-a-consensus-for-critical-data-fields-for-international-pediatric-antiphospholipid-syndrome-research/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology